CD16+B-NHL/DLBCL

Sylvia Zöphel1, Nadja Küchler1, Johanna Jansky1

  • 1Biophysics, Center for Integrative Physiology and Molecular Medicine (CIPMM), School of Medicine, Saarland University, Building 48, 66421, Homburg, Germany.

Molecular cancer
|September 28, 2024
PubMed
概括

较高的CD16+ T细胞水平表明侵略性非霍奇金B细胞淋巴瘤患者的结果更好,而较高的CD16+单细胞表明预后更差. 综合分析提供了精确的早期复发预测.

相关概念视频